LENZ Therapeutics

LENZ Therapeutics(LENZ)

SOLANA BEACH, CA
Biotechnology

Focus: Ophthalmology Treatments

LENZ Therapeutics is a life sciences company focused on Ophthalmology Treatments.

Ophthalmology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (1)

Pipeline & Clinical Trials

Aceclidine + Brimonidine
Eye Diseases
Phase 1
Clinical Trials (1)
NCT05936489Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
Phase 1
Phase 1
Clinical Trials (1)
NCT06270030Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia
Phase 1
Aceclidine+Brimonidine combination ophthalmic solution
Presbyopia
Phase 2
Clinical Trials (1)
NCT05294328Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Phase 2
PRX-100
Presbyopia
Phase 2
Clinical Trials (1)
NCT02554396Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
Phase 2
Aceclidine+tropicamide combination
Presbyopia
Phase 2
Clinical Trials (1)
NCT03201562A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
Phase 2
Aceclidine+Brimonidine combination ophthalmic solution
Presbyopia
Phase 2
Clinical Trials (1)
NCT05431543Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
Phase 2
Aceclidine+Brimonidine combination ophthalmic solution
Presbyopia
Phase 3
Clinical Trials (1)
NCT05656027Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
Phase 3
Aceclidine+Brimonidine combination ophthalmic solution
Presbyopia
Phase 3
Clinical Trials (1)
NCT06045299Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
Phase 3
Aceclidine+Brimonidine combination ophthalmic solution
Presbyopia
Phase 3
Clinical Trials (1)
NCT05753189Phase 3 Safety Study for the Treatment of Presbyopia Subjects
Phase 3
Aceclidine+Brimonidine combination ophthalmic solution
Presbyopia
Phase 3
Clinical Trials (1)
NCT05728944Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 1 approved product, 10 clinical trials
SEC Filings: 2 available
Portfolio Health
Launch1 (100%)
1 total products

Financials (FY2024)

R&D Spend
$60M18%
Net Income
-$70M
Cash
$35M

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 3 crawl cycles